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Abstract
Summary There is evidence that the use oral bisphospho-
nates can lead to osteronecrosis of the jaws (ONJ). Although
the occurrence of ONJ appears rare among oral bisphosph-
onates (BPs) users, it is important to know that it exists and
can be opportunely minimized.
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Introduction The purpose of this study is to evaluate the
association between BPs prescribed for the secondary pre-
vention of osteoporotic fractures and the occurrence of ONJ.
Methods An Italian record linkage claims database with a
target population of around 18 million individuals (6 million
over 55 years of age) constituted the data source. We con-
ducted a nested case–control study within a cohort of indi-
viduals aged 55+years old, who were discharged from
hospitals with a primary diagnosis of incident osteoporotic
fracture. The date related to the discharge diagnosis of ONJ
was the index date. Conditional logistic regression for
matched data was fitted to estimate the odds ratio (OR)
along with 95 % confidence intervals (95 % CI) for the
likely association between use of BPs and the risk of ONJ.
Results Any one of the 61 ascertained cases of ONJ (inci-
dence rate, 36.6 per 100,000 person-years) was matched to
20 controls for a total of 1120 controls. When the exposure
to BPs was modeled according to recency (i.e., exposure
time window prior to the index date) of use, the adjusted OR
(95 % CI) for current users was 2.8 (1.3–5.9) against never
users. The cumulative use of BPs has shown to increase the
incidence of ONJ among patients with primary osteoporotic
fractures, although not statistically significant risk has been
observed.
Conclusions Although the risk of BP-related ONJ appears
low in non-oncological indications, it is important to be
aware that it exists and to know how it may be predicted
and possibly minimized.
Keywords Bisphosphonates . Nested case–control study .
Osteonecrosis of the jaw . Osteoporotic fractures
Introduction
Osteonecrosis of the jaw (ONJ), a rare condition character-
ized by exposed necrotic bone in the maxillofacial region [1,
2], has received increasing attention since case reports
among patients exposed to bisphosphonates (BPs) were
published in 2003 [3, 4].
The ONJ clinical picture mainly consists of non-healing
ulcerated oral lesions and visible necrotic bone, which are
sometimes associated with a diffuse jaw or facial pain [2,
5–7]. The exact etiologic mechanisms remain unclear, but it
might relate, in part, to altered bone remodeling or local
tissue effects in susceptible patients [1, 8, 9].
Most affected patients have incurred ONJ after inva-
sive dental procedures that involved dental bone manip-
ulation, although spontaneous exposure of bone has
been also observed. Cofactors have not been firmly
established, although smoking, steroid use, anemia, hypox-
emia, diabetes, infections, and immune deficiency may be
important [2, 5–7]. Indeed, as only a minority of BPs
users develop ONJ, it is conceivable that individual
pharmacokinetic and pharmacodynamic genetic variations
may confer susceptibility or resistance in developing this
complication. Among genetic determinants, polymorphisms
on CYP2C8 gene [10] and of FDPcS gene [11] arise as
promising risk factors.
To date, most of the reported cases have been related to
zoledronic or pamidronic acid when they were administered
intravenously to control metastatic bone disease or multiple
myeloma [4, 12, 13], for which reported ONJ incidence
ranges from 4 to 10 %, and the mean time of onset varies
from 1 to 3 years [1, 14, 15].
Early case series also identified approximately 5 % of
the reported cases occurring in patients receiving oral
BPs [1, 8], primarily used for the prevention of osteo-
porotic fractures. However, limited data exist about the
ONJ risk with such medications, and most of the pub-
lished evidence are derived from surveillance data [16].
A study from Germany, which used information from the
Central Registry of ONJ, reported a prevalence among
patients treated with BPs for osteoporosis of 0.00038 %
[17]. In a survey of 8572 Kaiser Permanente respondents,
the prevalence of ONJ in patients receiving long-term (more
than 2 years) oral BP therapy ranged from 0.05 to 0.21 %,
depending on the duration of exposure [18]. Finally, in a
nationwide survey of oral and maxillofacial surgeons in Aus-
tralia, the incidence of ONJ among osteoporotic patient treated
weekly with alendronate was 0.01–0.04 %. Following dental
extractions, this rate increased to 0.09–0.34 % [14]. In addi-
tion, inferences from observational epidemiologic studies
published so far offer conflicting results, and in most of the
cases, they are subjected to unmeasured confounding and
biases [19–21].
Given the increasing number of persons taking oral BPs
for the treatment of osteopenia/osteoporosis [22], it is im-
portant to accurately determine the incidence of ONJ using
rigorous case ascertainment criteria and to assess the risk
associated with long-term use of such medications. We
therefore conducted a nested case–control study to evaluate
the possible association between the use of oral BPs pre-
scribed for the secondary prevention of osteoporotic frac-
tures and the occurrence of ONJ.
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Methods
Data source
The data used for this studywere obtained from the Bisphosph-
onates Effectiveness Safety Trade-off (BEST) network. It col-
lects record linkage encrypted information on patient
demographics, hospital discharge schemes (HDS), the related
surgical and/or diagnostic procedures [since January 1, 1998 to
December 31, 2007; coded by International Classification
Disease, 9th version, Clinical Modification (ICD9CM)], any
reimbursed drug prescription (since January 1, 2003 to De-
cember 31, 2007; coded by Anatomical Therapeutic Chemical
classification), and the mortality registers (since January 1,
2003 to December 31, 2007) from a target population of
around 18 million people residing in four Italian Regions and
in the catchments areas of ten Local Health Authorities (LHA).
The study was approved by the Local Research Ethics Com-
mittees of each Region or LHA being involved into the project.
Cohort selection
The process of cohort selection is depicted in Fig. 1. All
patients aged 55+years, who were discharged because of an
osteoporotic fracture during the period July 1, 2003–Decem-
ber 31, 2005, were identified. Fractures were selected
among ICD9CM codes (primary and secondary positions)
consistently associated to osteoporotic fractures site, (23–
27) such as vertebrae (codes: 733.13, 805*), pelvis (code:
808*), femur/hip (codes: 733.14, 820*, 821*), and tibia/
fibula (codes: 733.16, 823*) [23–26]. The date of the first
recorded HDS of osteoporotic fracture was considered as the
“entry date” of follow-up.
Patients were excluded if they had, before the entry date,
less than 6 months of tracking period, an evidence of hospi-
talization for osteoporotic fracture or fractures at multiple sites
(i.e., more likely to be associated with non-osteoporotic frac-
ture), Paget’s disease (code: 731*), and malignant neoplasms
(codes: 140 to 208). The prescription of BPs in the 6 months
prior to entry date has been also considered an exclusion
criterion. No cases of ONJ (see “Cases and controls definition”
section) were captured before the entry date.
Each participant accrued person-years of follow-up from
the entry date until the earliest of the following events: ONJ-
related diagnosis, occurrence of one of the exclusion criteria
(with the exception of osteoporotic fractures), death, trans-
ferring out of BEST catchment areas, or end of the study
period (December 31, 2007).
Cases and controls definition
Cases were members of the study cohort who had experi-
enced an ONJ event during the follow-up. Since there were
no specific ICD9CM codes for the ONJ-related events dur-
ing the study period, a four-step process identified ONJ
cases from the study population.
First, potential ONJ cases have been retrieved for main or
secondary diagnosis from ICD9CM and Current Procedural
Terminology billing codes from the regional or LHA regis-
tries of the HDS. In a preliminary evaluation, a highly
sensitive case-finding procedure has been implemented.
Subsequently, an adjudication committee composed by a
panel of experts in dentistry, oncology, geriatric, and phar-
macology selected from the preliminary list only diagnostic
codes and procedures that could have been most likely used
to describe or treat a necrotic lesion of the jaw. Second,
among the selected cases, additional information was col-
lected from the medical charts using a structured question-
naire. The questionnaire included information on descriptive
discharge diagnosis, tomography or panoramic imaging,
history of dental extraction, tissue biopsy, signs or symp-
toms. Third, the collected questionnaires were reviewed by
the study staff for excluding potential false positives (i.e.,
patients with direct or indirect evidence of cancer, trauma,
osteonecrosis at other bone sites as well as signs and/or
symptoms related to the main other oral–maxillary dis-
eases). Fourth, remaining cases were classified by two
ONJ experts as “definite” (i.e., 22 cases) if: (1) sign or
symptoms suggesting necrotic bone lesions, inflammatory
jaw condition not related to strict dental causes, and open
lesions/ulcers of the jaw were recorded. All lesions related
to soft tissues (e.g., recurrent aphthous ulcers) were pur-
posely identified and excluded; [5] (2) the ONJ was specif-
ically mentioned in the medical chart; and (3) pain was not
directly referred to dental extraction or other surgical pro-
cedures. The other cases not fulfilling these criteria were
classified as “probable” (i.e., 39 cases). For each case, up to
20 controls were randomly selected among the patients’
cohort. Controls were matched to their respective case by
sex, age (±3 years), month, and year of the cohort entry. The
date of ONJ-related diagnosis was the “index date,” and the
same date was assigned as the index date to the respective
matched controls.
Exposure assessment
Patients have been considered on BPs treatment once they
received a prescription between the entry date and the index
date. The number of days supplied from each prescrip-
tion has been calculated assuming a standard dosing
regimen, as assessed by the defined daily dose. It has also
been used to calculate the sum of days of BPs exposure (plus
28 days to account for potential hospital prescriptions) during
the entire follow-up. For each patient, adherence to BPs was
therefore estimated by dividing the sum of days of BPs expo-
sure with the follow-up [medical possession ratio (MPR)], and
Osteoporos Int
further classified into the following adherence levels: high
(MPR ≥80 %), intermediate (MPR=40–79 %), and low
(MPR <40 %).
Following the case and control selection, patients were
categorized into mutually exclusive categories of current
use, past use, and non-use, according to latest date of BPs
pharmacy claims supply before the index date. Current use
has been defined as latest date of exposure occurring within
1 year before the index date; past use as exposure interrup-
ted more than 1 year before the index date, and non-use as
no recorded BPs prescription at any time during follow-up.
Current users have been further subdivided into four cate-
gories (i.e., ≤90 days, from 91 to 179 days, from 180 to
364 days, and ≥365 days) according to the sum of days of
BPs exposure during follow-up.
Covariates
As covariates, we evaluated the patients’ demographics (i.e.,
age and gender) and the presence of risk factors for ONJ as
commonly described in the most recent guidelines on ONJ
[5, 7]: (1) concurrent drug use [i.e., antithrombotics, proton
Patients with a IC9CM diagnosis (entry date) 
likely due to osteoporotic fracture 
N=115,772 
Excluded 5659: subjects younger than 55 years 
N=77,261 
Excluded 3865: osteoporotic fractures prior the 
entry date  
N=73,396 
Excluded 2752: Bisphosphonates use prior the 
entry date 
N=70,644 
Excluded 5388: diagnosis of tumor prior the 
entry date 
N=65,256 
Final Cohort 
N=65,220
Controls
N=1120 
Cases
N=61 
Excluded 36: diagnosis of Paget disease prior 
the entry date 
N=65,220 
Censoring criteria (occurrence of): 
ONJ (related ICD9CM) 
Exclusion criteria (secondary fractures 
excluded) 
Death
End of the study period (December 31, 
2007) 
Fig. 1 Flow chart of cohort and case–control selection process
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pump inhibitors (PPIs), non steroidal anti-inflammatory drugs
(NSAIDs), beta-blockers, antidepressants, antiepileptic drugs,
lipid-lowering drugs, calcium and/or vitamin D supplements,
immunosuppressant, and corticosteroids; captured within 1
year before the index date]; (2) concurrent diseases (captured
any time before the index date), such as diabetes mellitus
(code 250* and use of antidiabetic drugs), vascular coagula-
tion disorders (codes 093.0, 286*, 287.1, 287.3 through 287.5,
440*, 441*, 443.1 through 443.9, 447.1, V43.4), and the
Charlson Comorbidity Index (CCI) as index of chronic sever-
ity degree. Occurrence of any osteoporotic fracture during
follow-up was not censored, and it was considered in the
case–control analysis.
Data analysis
Density method has been used in measuring the incidence of
ONJ. The number of events that occurred during follow-up
and the person-months cumulatively spent in the
corresponding periods by the cohort members constituted
the numerator and the denominator of the incidence rates,
respectively.
Statistical differences between cases and controls were
evaluated by means of χ2 or t tests for categorical and contin-
uous variables, respectively. Conditional logistic regression
for matched data was fitted to estimate the odds ratio (OR)
along with the corresponding 95% confidence intervals (95%
CI), for the association between use of BPs and the risk of
ONJ. After Mantel–Haenszel test, the OR estimates were
adjusted for those variables significantly (10 %) affecting the
crude relationship between BPs and ONJ.
To test the robustness of our findings, some sensitivity
analyses were performed. Firstly, the analyses were restrict-
ed to definite cases only. Secondly, because the allocation of
BPs therapy was not randomized and the indication for
treatment may be related to the risk of future health out-
comes, a propensity score (PS) matching design was carried
out with the aim of taking into account the confounding by
indication [27]. The PS was estimated at patient level by
performing a multivariable logistic regression. Each known
predictor of BPs exposure and ONJ occurrence, as well as
those risk factors for ONJ constituted the covariates vector
which established the propensity to BPs use. All variables
were imputed in the model in a non-parsimonious way accord-
ing to methodological literature [28]. Afterwards, cases and
controls were matched (1:20) by the corresponding PS within
±0.1. Finally, to account for the possible effect dilution due to
short-term BPs users, all models were rerun by excluding
individuals who begun the therapy less than 6 months before
the index date.
All analyses were performed using STATA 10.0 for Win-
dows. Statistical significance was defined as a p value less
than 0.05.
Results
From the BEST database, 115,772 patients with an HDS for
osteoporotic fracture were selected between January 1, 2003
and December 31, 2005. Of these, 65,220 patients aged
55 years and older, after the application of the exclusion
criteria, constituted the comprehensive study cohort (Fig. 1).
Incidence rates
During the follow-up, we identified 61 cases of ONJ (22
definite), with an incidence rate of 36.6 (95 % CI, 28.5–
46.9) per 100,000 person-years. An increased incidence has
been observed among patients with diabetes mellitus [77.3
(95 % CI, 46.6–128.4)], as well as among those being
prescribed corticosteroids during follow-up [58.3 (95 %
CI, 24.2–140.1)]. Higher incidence has been also reported
among BPs users [46.0 (95 % CI, 24.8–85.5)], when com-
pared with nonusers [35.2 (95 % CIs, 26.8–46.3)]. Among
BPs users, we have also observed a growing trend related to
the adherence levels, with incidence ranging from 27.3
(95 % CIs, 10.3–72.8) among low adherers (MPR<40 %)
to 111.7 (95 % CIs, 27.9–446.6) among high adherers
(MPR≥80 %).
Nested case–control study
All 65,220 eligible patients were followed up (median,
2.7 years), and 61 ONJ cases along with 1120 matched
controls were considered for the analysis. The character-
istics of the cases and controls at the index date are de-
scribed in Table 1. Overall, cases were more likely to have
comorbid conditions, as assessed by using the CCI, or by
diabetes prevalence (27.9 vs. 17 %). They were also more
likely to be prescribed with co-medications such as antith-
rombotics (50.8 vs. 30.5 %) and immunosuppressant (4.9
vs. 0.2 %). After adjustment for selected covariates, we
observed a nonstatistically significant increased risk of
ONJ (OR, 1.7; 95 % CI, 0.8–3.6) associated with BPs use.
However, when the analysis was restricted to current users,
a statistically significant 2.8-fold increased risk was reported
(OR, 2.8; 95 % CI, 1.3–5.9), when compared to nonusers
(Table 2). The statistical significance among current users
was confirmed in a sensitivity analysis which selected
propensity-matched controls (OR, 2.3; 95 % CI, 1.1–5.1).
Upon restriction to 22 definite ONJ cases and 440
matched controls, the association maintained similar risk
among current users (OR, 2.5; 95 % CI, 0.7–9.5). In such
analysis, also a longer exposure with oral BPs (i.e., 180–
364 days) showed a clearer trend toward an increased risk of
ONJ (OR, 4.2; 95 % CI, 0.5–41.4), although, due to the
small sample size, it did not reach the statistical significance.
Finally, the exclusion of individuals who started the therapy
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less than 6 months before the index date did not change the
results (data not shown).
Discussion
To the best of our knowledge, this is the first investigation
which estimated the risk of being exposed to oral BPs
among a series of ascertained cases of ONJ. In specific,
the exposure to BPs was 2.8-fold higher among patients
who incurred ONJ when compared with their matched con-
trols. In addition, although not statistically significant, a
growing duration of BPs use showed an association trend
toward an increased risk of ONJ occurrence.
In spite of numerous publications, very few evidence has
been able to draw definite conclusions about the strength of
Table 1 Characteristics of case
and controls at the index date
SD standard deviation, CCI
Charlson Comorbidity Index,
NSAIDs non steroidal anti-
inflammatory drugs, PPIs proton
pump inhibitors
aICD9CM coded diagnosis or an
antidiabetic prescription
Cases Controls
N061 % N01120 % p value
Gender, female 42 68.9 840 68.9 -
Age (mean±SD) 73.2±0.7 73.1±9.1 -
Comorbidity
CCI 0.001
0 21 34.4 687 56.3
1 22 36.1 299 24.5
2 7 11.5 139 11.4
3+ 11 18.0 95 7.8
Diabetes mellitusa 17 27.9 207 17.0 0.029
Osteoporotic fractures (secondary) 8 13.1 171 14.0 0.843
Vascular and coagulation disorders 6 9.8 30 2.5 0.001
Co-medications
Antithrombotics 31 50.8 372 30.5 0.001
PPIs 14 23.0 194 15.9 0.145
NSAIDs 11 18.0 215 17.6 0.935
Beta-blockers 11 18.0 117 9.6 0.032
Antidepressants 10 16.4 171 14.0 0.603
Antiepileptic drugs 6 9.8 69 5.7 0.175
Lipid-lowering drugs 6 9.8 111 9.1 0.845
Calcium and/or vitamin D supplements 6 9.8 134 11.0 0.779
Immunosuppressant drugs 3 4.9 2 0.2 <0.001
Corticosteroids 2 3.3 77 6.3 0.337
Table 2 Association between
exposure to oral BPs and ONJ
aAdjusted for diabetes, cortico-
steroids, PPIs
bCurrent use: the latest date of
exposure to BPs occurring with-
in 1 year before the index date;
past use: exposure to BPs inter-
rupted more than 1 year before
the index date
cCumulative use was assessed
from the start date until the index
date among current users
Cases
N061
Controls
N01220
Crude OR
(95 % CI)
Adjusted ORa
(95 % CI)
BPs use (any time)
No 51 (83.6) 1102 (90.3) Reference Reference
Yes 10 (16.4) 118 (9.7) 1.9 (0.9–3.8) 1.7 (0.8–3.6)
BPs use (recency of use)b
Past use 0 40 (3.3) – –
Current use 10 (16.4) 78 (6.4) 2.9 (1.3–6.0) 2.8 (1.3–5.9)
BP cumulative use (days)c
≤90 4 (6.6) 49 (4.0) 1.8 (0.6–5.1) 1.8 (0.6–5.2)
91–179 2 (3.3) 25 (2.1) 1.8 (0.4–8.1) 1.7 (0.4–7.8)
180–364 2 (3.3) 22 (1.8) 2.0 (0.5–9.1) 1.9 (0.4–8.6)
≥365 2 (3.3) 22 (1.8) 2.0 (0.5–9.1) 2.0 (0.4–9.8)
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the association between ONJ and oral BPs, in particular
when they are prescribed for preventing osteoporotic frac-
tures. Zavras et al. [19], analyzing medical claims from
approximately 20 million people in the USA, reported a
fourfold increased risk of jaw surgery associated with intra-
venous BPs, and a nonsignificantly increased association
with oral BPs. Pazianas et al. [20] used jaw surgery as a
surrogate marker for ONJ and did not find any association
with oral BPs. Etminan et al. [29] reported a significant
relative risk of 2.87, 2.43, and 3.34 of any-site aseptic
osteonecrosis for alendronate, etidronate, and risedronate,
respectively. Nevertheless, none of the mentioned studies
formally validated the outcome, thus making difficult to
provide definite explanations to their findings.
More recently, a case–control study [21] enrolling 191
validated ONJ cases and 573 controls in 119 dental practices
reported a strong association (OR012.2; 95 % CIs, 4.3–
35.0) between oral BPs and ONJ. However, this study
included cancer patients, thus increasing the potential for
residual confounding. A second limitation concerned the
fact that information about medication use was obtained
from telephone interviews. In these conditions, the likeli-
hood for a recall bias could be substantial because of the
high proportion of false negatives among controls, which
could result in a potential overestimation of the risk [30].
In our study, we addressed these potential biases by
excluding and censoring from the selected cohort patients
with cancer who could be exposed to chemotherapy and/or
parenteral BPs. Because of the short time window available
before the “entry date” and the likelihood of underdetection
of anticancer therapy issued at hospital level, we have also
used very restrictive criteria for excluding the potential
remaining cancer-related ONJ cases in the formal validation
of medical charts. For what concerns the exposure, because it
was assessed from pharmacy records, which could be
regarded as a virtually complete source of information, recall
bias was unlikely to occur.
Osteonecrosis of the jaw has been also associated with
duration of BPs treatment, with an estimated range of 1.6 to
4.7 years, depending on BPs type [1]. However, for non-
cancer patients (the vast majority of whom take oral BPs),
the ONJ risk seems to increase substantially after 5 years
[21]. In our study, we have found a statistically significant
association even after a median follow-up of 2.7 years, with
cumulative BP use shorter than expected. Selective prescrib-
ing was unlikely to occur since sensitivity analyses made
with propensity-matched controls showed results similar to
the main analysis. Therefore, such findings might be par-
tially explained by the inclusion into the cohort of greater-
risk patients, specifically those discharged with an osteopo-
rotic fracture.
This association is also supported by a biological ratio-
nale. Bisphosphonates affect the physiological bone
remodeling by inducing an inhibition of osteoclast recruit-
ment, decreasing osteoclast activity, and promoting osteo-
clast apoptosis. This process is exerted by inhibition of the
mevalonate and cholesterol biosynthetic pathways, thereby
reducing the production of lipids essential for protein pre-
nylation or posttranslational modification of the guanine
triphosphates (GTP) signaling which modulates the cellular
apoptosis. When GTP is uncontrolled, the osteoclast can be
disrupted by an irregular cytoskeletal rearrangement, mem-
brane ruffling, and intracellular vesicle transport [31–33]. In
this way, the long-term use of nitrogen-containing BPs leads
to the development of abnormal osteoclasts which degener-
ate into necrotic bone tissue. Moreover, BPs can exert a
direct inhibitory effect on cellular proliferation and angio-
genesis in the healing of alveolar bone after dental extraction
[34].
Our study has several noteworthy limitations. First, al-
though the present findings consistently support the hypoth-
esis of a duration–response relationship, the small sample
size, besides the lower than expected proportion of ONJ
patients exposed to oral BPs (10/61), did not allow us to
provide robust estimates about the effect of cumulative BPs
use. Second, we acknowledge the possibility of residual
false positives among validated cases, especially those cases
with inflammatory and suppurative jaw conditions, but
without any additional registered sign or symptom suggest-
ing necrotic bone lesions or open wounds/ulcers. However,
in our cohort, ONJ incidence among BPs users was 46.0
(95 % CI, 24.8.1–85.5) per 100,000 person-years, higher
than 1/10,000–1/100,000 range based on surveillance data
[7, 17], but in agreement with two surveys conducted in
Australia [14] and in the USA [18], which reported rates
among patient exposed with oral BPs from 0.01 to 0.21 %.
Furthermore, although the smaller number of cases did not
permit to reach the statistical significance, the results from
the sensitivity analysis conducted using only “definite”
cases still indicated an increased risk among oral BP users,
with a more evident cumulative effect of BPs. Thirdly, by
assuming that patients who initiated the therapy had to be
exposed at least 6 months to develop the ONJ, those with
less than 6 months before the index date could have diluted
the effect size. However, their exclusion from the analysis
yielded similar results. Fourthly, the fact that ONJ was
known as a BP-related disease could have introduced a
detection bias among the exposed patients. Finally, some
unmeasured confounders such as alcohol and smoking
could have partly explained the association between the
exposure and the outcome. Nevertheless, the presence of a
duration-dependent association should overcome these two
shortcomings.
From a clinical viewpoint, it cannot be denied that these
medications have a demonstrated efficacy. In clinical trials,
they have been associated with a reduction of incidence of
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fractures related to postmenopausal osteoporosis by 20 to
45 % [35]. Several studies, conducted with claims databases
in a "real-world setting," confirmed that greater adherence to
BPs was significantly associated with a relative risk reduc-
tion of fractures after 24 months of follow-up ranging from
7 to 20 % [36]. Nevertheless, although the risk of BP-related
ONJ is low in non-oncological indications, it is important to
be aware that it exists and to know how this clinical issue
may be predicted and possibly minimized.
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